Cancer

Title
A Blinded, Randomized Study with Zoledronic Acid or Denosumab to Treat Bone Disease in Subjects With Newly Diagnosed Multiple Myeloma
Trial Number
204402051612
Number of Participants
1,520
Principal Investigator

Patrick Stiff

M.D.
Hematology/Oncology
Coleman Professor of Oncology
Eligibility

Adult subjects with newly diagnosed multiple myeloma and at least one lytic bone lesion, who have had no previous treatment (short course of dexamethasone is acceptable) and are planned for frontline anti-myeloma therapy. Subjects must be ECOG 0, 1 or 2; have adequate organ function; and be IV bisphosphonate-naive.

Purpose

To determine if denosumab is equal to zoledronic acid by checking bone deterioration or strength in patients with multiple myeloma.

Enrollment

(708) 327-2241

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.